High‐dose methotrexate with leucovorin rescue in patients with unresectable non‐small cell carcinoma of the lung

M. Brower, D. N. Carney, D. C. Ihde, J. Eddy, P. A. Bunn, M. H. Cohen, F. R. Pelsor, M. J. Matthews, J. D. Minna

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

Thirty‐one patients with unresectable non‐small cell carcinoma of the lung (19 adenocarcinoma, 7 large cell carcinoma, 4 squamous cell carcinoma, 1 mixed histology) were treated with one of two intravenous infusion schedules of high dose methotrexate with leucovorin rescue. First, 14 patients received methotrexate in escalating doses from 1.5 to 12 g/m2 over 6 hours followed immediately with leucovorin 15 mg/m2 for 12 doses every 6 hours; there were no complete or partial responses among these 14 patients. Then, 17 patients were treated with a loading bolus of 50 mg/m2 intravenous methotrexate followed by a 30‐hour continuous infusion of 1.5 g/m2. Leucovorin 15 mg/m2 every 6 hours for 12 doses was begun at the end of the infusion. There were 3 partial responses among the 17 patients in this group. The results demonstrate that both 6‐ and 30‐hour infusions of high‐dose methotrexate regimens can be given safely to middle aged adult patients, but the overall 10% response rate does not appear to be significantly different than the results with standard‐dose methotrexate.

Original languageEnglish (US)
Pages (from-to)1778-1782
Number of pages5
JournalCancer
Volume52
Issue number10
DOIs
StatePublished - Nov 15 1983

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'High‐dose methotrexate with leucovorin rescue in patients with unresectable non‐small cell carcinoma of the lung'. Together they form a unique fingerprint.

  • Cite this